Leukemia, Myelomonocytic, Chronic research hub

Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia

This study is looking at a new medicine called pacritinib for a type of blood cancer called advanced chronic myelomonocytic leukemia (CMML). Researchers want to see if pacritinib works better and is safer than the usual treatment, hydroxyurea. Participants will take one of these medicines for nearly a year.